Bioage Labs (NASDAQ:BIOA) Bolsa

Bioage Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

<ul>
<li>Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy</li>
<li>Data support development of next-generation APJ agonists for obesity and key comorbidities</li>
</ul>

News

BIOA

Reported Saturday, BioAge Labs Presents Preclinical Data Showing APJ Agonism Enhances Glycemic Control And Cardioprotection In Diabetic Obesity And HFpEF

Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases
New data deepen platform insights into the biology of resilience across multiple therapeutic indications
EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway.
Through its collaboration with Norwegian diagnostics company Age Labs AS [<a href="https://www.globenewswire.com/Tracker?data=3h4mFEdXoGRr75IBgmUrihV2rKdUNUJElPtzEq2yXm5gj-DtAZHPEt96sJC5W8dUHhqlohgZhnBymqFbGUzwM01M_i3QlZiFhlF4xLv70fXSN-1WHdb8B_7lO-KYfdR-ZFRU3bg6SV4Kiabq1yD6if4jp2P6odI5XKX9pN-fG6B7Rd5UC5ps-0cIlZJyfiO3s_xaiZyuNvYx-holkv3M9g==">link</a>], BioAge will profile more than 17,000 individual samples—collected over decades of aging from 6,000+ HUNT participants—to generate millions of molecular readouts. Analyses of these data, coupled with detailed health and clinical outcomes of the participants, will significantly expand the proprietary human aging data that power BioAge's drug-discovery platform. The Company has exclusive access for the purpose of drug discovery to data generated by the partnership.

Biotech

General

BioAge Labs To Profile 17,000+ HUNT Biobank Samples In Norway To Accelerate Aging-Related Drug Target Discovery

IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end
BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing

BioAge Labs Completes IND-Enabling Studies For BGE-102 And Advances Candidate Toward Clinic

Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) by 32.08 percent. This is a 95.36 percent increase over losses of $(7.76) per share from the same period last year. The company reported $1.45 million in sales this quarter.

Earnings

Earnings Beats

Bioage Labs Q1 EPS $(0.36) Beats $(0.53) Estimate, Sales $1.45M

Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Neutral and lowers the price target from $7 to $5.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Bioage Labs, Lowers Price Target to $5

Full Year 2024 Financial Results
Research and development expenses were $59.0 million for the year ended December 31, 2024, compared to $33.9 million for the same period in 2023. The $25.1 million increase in research and development expenses was primarily attributable to a $22.8 million increase in costs related to the development of azelaprag driven by the Phase 2 STRIDES trial and costs related to the manufacture of azelaprag.
General and administrative expenses were $19.2 million for the year ended December 31, 2024, compared to $14.5 million for the same period in 2023. The $4.7 million increase was primarily attributable to an increase in stock-based compensation expense associated with option grants issued in 2024 to employees, executives, board members and advisors.
Net loss was $71.1 million for the year ended December 31, 2024, or $6.63 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $63.9 million, or $38.17 per weighted-average common share outstanding, basic and diluted, for the same period in 2023.
As of December 31, 2024, BioAge had approximately $354.3 million in cash and cash equivalents. Based on our current operating plan, BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029.

BioAge Labs FY24 EPS $(6.63) Up From $(38.17) YoY

Morgan Stanley analyst Jeffrey Hung assumes Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Underweight rating and announces Price Target of $5.

Initiation

Morgan Stanley Assumes Bioage Labs at Underweight, Announces Price Target of $5

BioArctic AB's &nbsp;partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal.

ESAIY

BioArctic And Eisai's Lecanemab Denied By Therapeutic Goods Administration Of Australia, Delaying Access For Alzheimer's Patients

William Blair analyst Andy Hsieh initiates coverage on Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Market Perform rating.

William Blair Initiates Coverage On Bioage Labs with Market Perform Rating

Advancement of next-generation APJ agonists with discontinuation of azelaprag
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&amp;D
RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced company updates for its programs and platform.
•&nbsp;Advancement of next-generation APJ agonists with discontinuation of azelaprag
BioAge has terminated development of azelaprag, an orally available small molecule agonist of APJ, for obesity and other chronic diseases. The decision follows observations of liver transaminitis without clinically significant symptoms, and without clear dose dependence, in some patients in the azelaprag arms of the STRIDES Phase 2 clinical trial for obesity (<a href="https://www.globenewswire.com/Tracker?data=6hETRD3ff7cnLvUiSBWq9wR9Z0Aio0CfBsoQJZkBTm9q4SVQpvwYGxjlYUFmqtNVuPYnsAq8uhr0ozDzZYVhdNlLJyBq1uaABDo2j53a27SmE0Mq1o23dSzW2xszSX_PWAy6LM8SZJaPH4sjwcR4yfQXvV-e1CqUfcbDObJq5cKvTA8giOyPc-_GdkmLrA0JO1l-GoH5n9ogoSVdjT99psnT52gQ5jN2OAs9jfZ4KCzZI1q2mNewKQPuDFM5lMNB4fDcM67qgaZQRA-DcLYlMHY7uFKk9UCLfOvJXm2b59L584kBX973rwDtSAaGfv1aHqhU5B4z5Yz_Ia22VSDnq2LoQUxg0uRkNBZ0usv_7AKSZHyHWrdXJzxQsXtx0hknJ6dpVcCscZ8Zff4NtS9g5_kECKb2fUnt_N-jcv4emFBoCIgf-2MVE864c78CFdUW8v6JbwStqPEp-eYmjNpiUg==">link</a>).
BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025.
•&nbsp;Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinctive structural and biological properties and include molecules that penetrate the blood–brain barrier, for diseases associated with neuroinflammation. The Company has nominated a member of this class, the orally available, small-molecule brain-penetrant NLRP3 inhibitor BGE-102, as a development candidate. The structurally novel drug has potential best-in-class features, including high potency and high brain penetration, an important attribute for a compound that could be used for treatment of neuroinflammation linked to conditions such as obesity. IND-enabling experiments for BGE-102 are currently underway, and Phase 1 SAD data are anticipated by the end of 2025.
•&nbsp;Expansion of discovery efforts based on novel insights from BioAge's platform, including collaborations with Novartis and Lilly
BioAge continues to leverage its discovery platform, which analyzes longitudinal human aging data to reveal the key molecular drivers of healthy aging to discover novel targets and molecules, via internal development programs and ongoing strategic collaborations.
In December, BioAge announced a multi-year research collaboration with Novartis to identify and validate novel therapeutic targets at the intersection of aging biology and exercise, combining BioAge's longitudinal human aging datasets with Novartis expertise in exercise biology. Under the terms of the agreement, BioAge will receive up to $20 million in upfront payments and research funding, plus up to $530 million in future long-term research, development, and commercial milestones (<a href="https://www.globenewswire.com/Tracker?data=6hETRD3ff7cnLvUiSBWq99sjD8Q_cuKxs60y_HtGgJEd-0udOrvZZGvSNag8xlKBktO7EhsRwY6bKvwcNHTt9Si6pdTssMjVhcxFa-UEcaul_xYdBVbow8tMSU0xXZ9HckUmIfAcalXXs8yF7_ckCXAFsX0b5ISqdGdfBfGYpCtwGeENP6Sx7Gu10_GD9hJcC3CLDI4MH3P2fBfvmGEkgq_8ymgCNFDl2Bd1J-uRE1PmCIf4nSVNexXzY4ZAT0lbiycqL0PjGXCk3XDcXu9Ic_1SBcTUXrVD6Diq5ND7tWfSF14DoFPOTJmuEs0o2KlyA1TYboG4ZNmJxKQ8X8-xCQ==">link</a>).
BioAge has also entered a strategic collaboration with Lilly ExploR&amp;D (part of Lilly Catalyze360) to discover two therapeutic antibodies that address novel metabolic aging targets identified by BioAge's discovery platform.
•&nbsp;Financial update
As of September 30, 2024, BioAge had approximately $334.5 million in cash and cash equivalents. This amount is not inclusive of the additional $27.6 million net fees from the exercise of the IPO's greenshoe option on October 1, 2024. Existing cash and cash equivalents extend cash runway beyond 2029.

BioAge Discontinues Azelaprag Due To Liver Issues, Advances Next-Gen APJ Agonists; Nominates NLRP3 Inhibitor BGE-102, Phase 1 Data Expected By End 2025

WIIM

BioAge Labs shares are trading higher after the company announced a multi-year collaboration with Novartis to discover novel targets for therapies addressing age-related diseases.

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging
Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones
RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a multi-year research collaboration with Novartis. The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate the beneficial effects of physical exercise.

Contracts

BioAge Labs Announces Multi-Year Collaboration With Novartis To Discover Novel Targets For Therapies That Address Age-Related Diseases And Conditions; Novartis To Pay Up To $20M Comprising Upfront Payments And Research Funding; BioAge May Receive Up To $530M In Future Long-Term Research, Development, And Commercial Milestones

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CRVO

IPHA

IZTC

RADX

RVNC

SONN

STRM

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.
The Dow traded down 0.24% to 44,533.63 while the NASDAQ fell 0.44% to 19,772.99. The S&amp;P 500 also fell, dropping, 0.45% to 6,063.09.
Check This Out: <a href="https://www.benzinga.com/24/12/42391708/tesla-to-370-here-are-10-top-analyst-forecasts-for-monday">Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday</a>
Leading and Lagging Sectors Energy shares jumped by 0.5% on Monday.
In trading on Monday, communication services shares fell by 1.2%.
Top Headline
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares shot up 308% to $1.27 after the company announced a collaboration with Texas Instruments for advanced driver assistance systems and autonomous driving solutions.</li>
<li>Shares of Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) got a boost, surging 58% to $0.9169. Shares of US-listed Chinese stocks traded higher following reports suggesting Chinese officials would embrace a &#8216;moderately loose&#8217; monetary policy.</li>
<li>Pactiv Evergreen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTVE#NASDAQ">PTVE</a>) shares were also up, gaining 19% to $17.42 after the company announced it will merge with Novolex in which Pactiv shareholders will receive $18.00 per share in cash.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) shares dropped 76% to $4.88 as the company announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) were down 58% to $1.4401 after the company announced a definitive agreement with investors for the purchase and sale of 18.75 million ordinary shares, expecting gross proceeds of $15 million.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) was down, falling 11% to $11.53 after the company announced a $500 million offering of convertible senior notes.</li>
</ul>
Commodities In commodity news, oil traded up 2% to $68.57 while gold traded up 1% at $2,686.30.
Silver traded up 3.4% to $32.645 on Monday, while copper rose 1.8% to $4.2725.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.14%, Germany's DAX fell 0.19% and France's CAC 40 rose 0.72%. Spain's IBEX 35 Index fell 0.50%, while London's FTSE 100 rose 0.52%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42390276/this-analyst-with-86-accuracy-rate-sees-around-21-upside-in-chewy-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 86% Accuracy Rate Sees Around 21% Upside In Chewy &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

LDTC

PTVE

RIOT

Crude Oil Gains 2%; BioAge Labs Shares Plunge

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Monday.
Following the market opening Monday, the Dow traded down 0.18% to 44,562.45 while the NASDAQ fell 0.68% to 19,724.61. The S&amp;P 500 also fell, dropping, 0.51% to 6,059.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42391708/tesla-to-370-here-are-10-top-analyst-forecasts-for-monday">Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday</a>
Leading and Lagging Sectors Energy shares jumped by 1.2% on Monday.
In trading on Monday, communication services shares fell by 1.4%.
Top Headline
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares shot up 336% to $1.3280 after the company announced a collaboration with Texas Instruments for advanced driver assistance systems and autonomous driving solutions.</li>
<li>Shares of Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) got a boost, surging 126% to $1.3050. Shares of US-listed Chinese stocks traded higher following reports suggesting Chinese officials would embrace a &#8216;moderately loose&#8217; monetary policy.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares were also up, gaining 83% to $0.8402.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) shares dropped 76% to $4.8350 as the company announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) were down 57% to $1.4501 after the company announced a definitive agreement with investors for the purchase and sale of 18.75 million ordinary shares, expecting gross proceeds of $15 million.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) was down, falling 45% to $10.50.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $68.64 while gold traded up 1.2% at $2,692.00.
Silver traded up 3.6% to $32.735 on Monday, while copper rose 2.1% to $4.2825.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX fell 0.1% and France's CAC 40 rose 0.8%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.5%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42390276/this-analyst-with-86-accuracy-rate-sees-around-21-upside-in-chewy-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 86% Accuracy Rate Sees Around 21% Upside In Chewy &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ASST

Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital raised the price target for Maplebear Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) from $49 to $56. Loop Capital analyst Rob Sanderson maintained a Buy rating. Maplebear shares closed at $44.19 on Friday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays boosted the price target for Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) from $173 to $187. Barclays analyst Benjamin Budish maintained an Overweight rating. Intercontinental Exchange shares closed at $155.93 on Friday. <a href="https://www.benzinga.com/quote/ICE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) price target from $151 to $193. Wells Fargo analyst Roger Read upgraded the stock from Equal-Weight to Overweight. Hess shares settled at $141.53 on Friday. <a href="https://www.benzinga.com/quote/HES/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $82 to $94. Morgan Stanley analyst Betsy Graseck upgraded the stock from Equal-Weight to Overweight. Bank of New York Mellon shares closed at $80.51 on Friday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) price target from $45 to $7. Citigroup analyst Samantha Semenkow downgraded the stock from Buy to Neutral. BioAge Labs shares closed at $20.09 on Friday.  <a href="https://www.benzinga.com/quote/BIOA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group boosted RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $290 to $330. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating on the stock. RH shares closed at $376.07 on Friday. See how other analysts view this stock.</li>
<li>Baird raised the price target for VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) from $200 to $250. Baird analyst Robert Oliver upgraded the stock from Neutral to Outperform. VeriSign shares settled at $191.14 on Friday. <a href="https://www.benzinga.com/quote/VRSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) price target from $300 to $330. Needham analyst Chris Pierce maintained a Buy rating. Carvana shares closed at $251.21 on Friday. <a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ascendiant Capital cut the price target for Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) from $7.25 to $7. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Lucid Diagnostics shares closed at $0.8401 on Friday. <a href="https://www.benzinga.com/quote/LUCD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $295 to $370. Deutsche Bank analyst Edison Yu maintained a Buy rating. Tesla shares closed at $389.22 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="467" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-1024x467.png" alt="" class="wp-image-683364" style="width:639px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-1024x467.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-300x137.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-768x350.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65.png 1220w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

CART

CVNA

LUCD

TSLA

VRSN

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) fell sharply in today's pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with Tirzepatide <a href="https://www.benzinga.com/quote/BIOA/news">for the treatment of obesity.</a>
BioAge Labs shares tumbled 68.6% to $6.30 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Palmer Square Capital BDC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NASDAQ">PSBD</a>) shares tumbled 18.3% to $13.00 in pre-market trading.</li>
<li>Bicara Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) fell 14.7% to $18.00 in pre-market trading after gaining 8% on Friday.</li>
<li>ZJK Industrial Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 10.9% to $12.55 in pre-market trading.</li>
<li>Heritage Commerce Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) declined 9.7% to $9.50 in pre-market trading.</li>
<li>Bel Fuse Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) declined 7.1% to $78.00 in pre-market trading.</li>
<li>Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) fell 6.7% to $12.08 in pre-market trading. Riot Platforms announced a proposed private offering of $500 million of convertible senior notes.</li>
<li>ZimVie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) fell 6.5% to $13.03 in pre-market trading.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) declined 5.8% to $378.00 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

BCAX

BELFB

HTBK

PSBD

ZIMV

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BioAdge Labs shares are trading lower after Jefferies downgraded the stock from Buy to Hold and Citigroup downgraded the stock from Buy to Neutral. Additionally, both firms cut their price target on the stock to $7.

On Friday, BioAge Labs&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42374184/bioage-labs-announces-discontinuation-of-strides-phase-2-clinical-trial-evaluating-azelaprag-in-co" rel="noreferrer noopener">drug candidate, azelaprag</a>.
STRIDES was being conducted in collaboration with Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025.
The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.
STRIDES is a Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older.
Tirzepatide is an active ingredient of Eli Lilly&#8217;s popular Zepbound and Mounjaro.
The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly).
An azelaprag monotherapy arm was included to provide additional safety information.
The company said no transaminase elevations were observed in the tirzepatide only treatment group.
Of 204 subjects enrolled in STRIDES, 11 subjects in the azelaprag treatment groups were observed to have transaminase (liver enzymes) elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled.
Clinical follow-up of enrolled subjects will continue off-drug. The company intends to further analyze available STRIDES clinical data from all enrolled subjects and share updated plans for azelaprag in the first quarter of 2025.
The company&#8217;s brain-penetrant NLRP3 inhibitors are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation linked to metabolic and neurodegenerative diseases.
As of September 30, BioAge had approximately $334.5 million in cash and cash equivalents, which is expected to be sufficient to fund operations and capital <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41825231/bioage-labs-reports-third-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">expenses into 2029</a>.
In October, BioAge Labs closed its upsized initial public offering of 12.65 million shares at <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41129276/bioage-labs-announces-closing-of-initial-public-offering-full-exercise-of-underwriters-option-to-p" rel="noreferrer noopener">$18 per share</a>.
Price Action: BIOA stock is down 70% at $6.03 during the premarket session at last check Monday.
Photo via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42372905/lululemons-strong-earnings-and-share-buyback-push-analysts-to-increase-price-targets-details-here" target="_blank" rel="noreferrer noopener">Lululemon&#8217;s Strong Earnings and Share Buyback Push Analysts to Increase Price Forecast</a></li>
</ul>

Health Care

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Citigroup analyst Samantha Semenkow downgrades Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) from Buy to Neutral and lowers the price target from $45 to $7.

Downgrades

Citigroup Downgrades Bioage Labs to Neutral, Lowers Price Target to $7

Legal

Press Releases

Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra LifeSciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Comments

Bioage Labs

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL